AbbVie beats forecasts, as Humira sales keep soaring
US drugmaker AbbVie (NYSE: ABBV), now in its second year as an independent spin-out for Abbott, pleased investors with its first-quarter 2014 financials, fuelled by continued growth for its blockbuster rheumatoid arthritis drug Humira (adalimumab), already the current best-selling drug worldwide.
AbbVie posted a 5.4% rise to $4.56 billion in global revenues, beating Wall Street expectations of $4.33 billion. Without the impact of a stronger US dollar, sales would have risen 6.7%. Net earnings for the quarter were up a modes7 1.2% to $980 million, or $0.61 per share. Excluding special charges, AbbVie’s earnings per share were $0.71 (above previous guidance in the range of $0.67-$0.69), beating analysts’ average expectations of $0. 68, according to Thomson Reuters I/B/E/S. AbbVie shares rose 2.4% to $50.51 in early trading on Friday. The stock had gained 11% in the 12 months through the previous day, noted Bloomberg.
Full-year 2014 outlook
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze